Vnitr Lek 2016, 62(4):305-307

Beta-blockers and chronic obstructive pulmonary disease

Milan Sova1,*, Monika Kamasová2, Jan Václavík2, Eliška Sovová2,3, Lenka Hajdová1, Vítězslav Kolek1
1 Klinika plicních nemocí a tuberkulózy LF UP a FN Olomouc
2 I. interní klinika - kardiologická LF UP a FN Olomouc
3 Klinika tělovýchovného lékařství a kardiovaskulární rehabilitace LF UP a FN Olomouc

This general article discusses the problems of beta-blockers use in patients with chronic obstructive pulmonary disease (COPD). Its aim is to refute exaggerated concerns of physicians over possible undesirable effects of beta-blockers on the patient respiratory functions and present new data on the effects of beta-blockers on the extent of COPD exacerbations, bronchial reactivity and mortality of patients.

Keywords: beta-blockers; chronic obstructive pulmonary disease; undesirable effects of beta-blockers

Received: October 23, 2015; Accepted: December 3, 2015; Published: April 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sova M, Kamasová M, Václavík J, Sovová E, Hajdová L, Kolek V. Beta-blockers and chronic obstructive pulmonary disease. Vnitr Lek. 2016;62(4):305-307.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kuller LH, Ockene JK, Townsend M et al. The epidemiology of pulmonary function and COPD mortality in the multiple risk factor intervention trial. Am Rev Respir Dis 1989; 140(3 Pt 2): S76-S81. Go to original source... Go to PubMed...
    2. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107(11): 1514-1519. Go to original source... Go to PubMed...
    3. Malerba M, Montuschi P, Radaeli A et al. Role of beta-blockers in patients with COPD: current perspective. Drug Discov Today 2015; 20(11): 129-135. Go to original source... Go to PubMed...
    4. Minor DS, Meyer AM, Long RC et al. β-Blockers and chronic obstructive pulmonary disease: inappropriate avoidance? J Clin Hypertens (Greenwich) 2013; 15(12): 925-930. Go to original source... Go to PubMed...
    5. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33(14): 1787-1847. Erratum in Eur Heart J 2013; 34(2): 158. Go to original source... Go to PubMed...
    6. Salpeter S, Ormiston T, Salpeter E et al. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002; 2(2): CD003566. Go to original source... Go to PubMed...
    7. Short PM, Lipworth SI, Elder DH et al. Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011; 342: d2549. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.d2549>. Go to original source... Go to PubMed...
    8. van der Woude HJ, Zaagsma J, Postma DS et al. Detrimental effects of β-blockers in COPD: a concern for nonselective β-blockers. Chest 2005; 127(3): 818-824. Go to original source... Go to PubMed...
    9. Hawkins NM, MacDonald MR, Petrie MC et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail 2009; 11(7): 684-690. Go to original source... Go to PubMed...
    10. Lin R, Peng H, Nguyen LP et al. Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of 'beta-blockers' in a murine asthma model. Pulm Pharmacol Ther 2008; 21(1): 115-124. Go to original source... Go to PubMed...
    11. Ni Y, Shi G, Wan H. Use of cardioselective β-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials. J Int Med Res 2012; 40(6): 2051-2065. Go to original source... Go to PubMed...
    12. Mentz RJ, Wojdyla D, Fiuzat M et al. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol 2013; 111(4): 582-587. Go to original source... Go to PubMed...
    13. Kubota Y, Asai K, Furuse E et al. Impact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2015; 10(1): 515-523. Dostupné z DOI: <http://dx.doi.org/10.2147/COPD.S79942>. Go to original source... Go to PubMed...
    14. Kotlyar E, Keogh AM, Macdonald PS et al. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant 2002; 21(12): 1290-1295. Go to original source... Go to PubMed...
    15. Sirak TE, Jelic S, Le Jemtel TH. Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2004; 44(3): 497-502. Go to original source... Go to PubMed...
    16. Camsari A, Arikan S, Candan A et al. Metoprolol, a β-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. Heart Vessels 2003; 18(4): 188-192. Go to original source... Go to PubMed...
    17. Albouaini K, Andron M, Alahmar A et al. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis 2007; 2(4): 535-540. Go to PubMed...
    18. Maffei A, Lembo G. Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis 2009; 3(4): 317-327. Go to original source... Go to PubMed...
    19. Bhatt SP, Wells JM, Kinney GL et al. β-Blockers are associated with a reduction in COPD exacerbations. Thorax 2016;71(1):8-14; 207251. Dostupné z DOI: <http://dx.doi.org/doi:10.1136/thoraxjnl-2015-207251>. Go to original source... Go to PubMed...
    20. Du Q, Sun Y, Ding N et al. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. PLoS One 2014; 9(1): e113048. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0113048>. Go to original source... Go to PubMed...
    21. Rutten FH, Zuithoff NP, Hak E et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170(10): 880-887. Go to original source... Go to PubMed...
    22. Farland MZ, Peters CJ, Williams JD et al. β-Blocker use and incidence of chronic obstructive pulmonary disease exacerbations. Ann Pharmacother 2013; 47(5): 651-656. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.